Teva Expands Biosimilar Portfolio with FDA Approval of DEGEVMA for Oncology Indications

  • Teva's DEGEVMA (denosumab-adet) received FDA approval on September 28, 2026, as a biosimilar to Amgen's Xgeva® (denosumab).
  • DEGEVMA is indicated for preventing bone complications in advanced cancer patients, treating giant cell tumor of bone, and managing hypercalcemia of malignancy.
  • This approval follows the March 2026 FDA approval of PONLIMSI (denosumab-adet), completing Teva's denosumab biosimilar portfolio for both Xgeva® and Prolia® indications.
  • Teva plans to launch DEGEVMA and PONLIMSI in the U.S. in the coming months.

Teva's FDA approval of DEGEVMA strengthens its position in the biosimilars market, particularly in oncology-related bone disease and osteoporosis care. The approval aligns with Teva's strategy to expand its innovative and biosimilar medicines pipeline, aiming to reduce healthcare costs and broaden patient access to complex biologics. The move comes amid increasing industry focus on biosimilars as a means to drive down systemic healthcare expenditures.

Market Penetration
How Teva will position DEGEVMA and PONLIMSI against Amgen's established denosumab products in the oncology and osteoporosis markets.
Regulatory Dynamics
Whether the FDA's approval process for biosimilars will accelerate or face new scrutiny as more complex biologics enter the market.
Execution Risk
The pace at which Teva can commercialize its biosimilar portfolio while maintaining profitability under its Pivot to Growth strategy.